EXEL or CSLLY: Which Is the Better Value Stock Right Now? [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits. Currently, Exelixis has a Zacks Rank of #2 (Buy), while CSL Limited Sponsored ADR has a Zacks Rank of #3 (Hold). Investors should feel comfortable knowing that EXEL likely has seen a stronger improvement to its earnings outlook than CSLLY has recently. But this is only part of the picture for value investors. Value investors are also interested in a number of tried-and-true
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership SummitBusiness Wire
- Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Barclays PLC from $25.00 to $29.00. They now have an "equal weight" rating on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its price target raised by analysts at Citigroup Inc. from $38.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat
- Exelixis, Inc. (NASDAQ: EXEL) had its "equal weight" rating re-affirmed by analysts at Stephens. They now have a $29.00 price target on the stock.MarketBeat
EXEL
Earnings
- 2/11/25 - Beat
EXEL
Sec Filings
- 2/14/25 - Form 144
- 2/14/25 - Form 144
- 2/14/25 - Form 144
- EXEL's page on the SEC website